Nepexto (Etanercept)

Etanercept is a soluble TNF receptor fusion protein that binds circulating TNF‑alpha and TNF‑beta molecules. By neutralising these cytokines, it blocks their interaction with cell‑surface TNF receptors, thereby suppressing the inflammatory signalling pathways that drive autoimmune disease.

The dosage of Nepexto is individualized by the prescribing healthcare professional based on the specific indication, disease severity, patient weight, and response to therapy. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

Safety data for etanercept in pregnancy and lactation are limited, and the product’s pregnancy category is not established. Women who are pregnant, planning pregnancy, or breastfeeding should discuss potential risks and benefits with their healthcare provider before using Nepexto.

To request Nepexto, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain handling) and import documentation.

Nepexto (etanercept) is a fusion protein that binds both TNF‑alpha and TNF‑beta, whereas many other TNF inhibitors are monoclonal antibodies that target only TNF‑alpha. Clinical efficacy is comparable across approved indications, but differences in molecular structure can influence dosing frequency, immunogenicity and specific safety profiles.

Nepexto must be stored at 2‑8 °C (refrigerated). Keep the product in its original packaging, protect it from light, and avoid freezing or shaking the vial. Do not use the medication if it has been exposed to temperatures outside the recommended range.

Nepexto is given by subcutaneous injection, typically into the thigh, abdomen or upper arm. The injection is performed by a trained healthcare professional or, after proper instruction, by the patient or caregiver using a pre‑filled syringe or auto‑injector device.

Serious risks include severe infections (such as tuberculosis or bacterial sepsis), malignancies (including lymphoma and skin cancers), new or worsening heart failure, demyelinating disorders, and lupus‑like syndrome. Patients should be monitored regularly and report any signs of infection, respiratory symptoms, or unusual neurological changes promptly.

Nepexto is contraindicated in patients with known hypersensitivity to etanercept or any component of the formulation. It should also be avoided in individuals with active, severe infections, uncontrolled heart failure, or those receiving live vaccines. A thorough medical assessment is required before initiating therapy.